NEWS & RELEASE
- Launch of “Avarept® Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition（PDF）
- Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition（PDF）
- Senju has developed and obtained approval for a BAC-free formulation of Aibeta® combination eye drops（PDF）
- Announcement of Licensing Agreement with Brill International（PDF）
